Overview

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Status:
NOT_YET_RECRUITING
Trial end date:
2031-10-10
Target enrollment:
Participant gender:
Summary
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborator:
Daiichi Sankyo
Treatments:
Cetuximab
patritumab deruxtecan